New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.» Read More
Bristol-Myers Squibb is developing the drug, which is already approved in Europe, in partnership with AstraZeneca. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
Bristol-Myers is developing the drug, which is already approved in Europe, in partnership with AstraZeneca Plc. The FDA typically follows the advice of its advisory panels, but is under no obligation to do so.
LONDON, Dec 12- Bristol-Myers Squibb is to share intellectual property rights on an important HIV/AIDS drug in a patent pool designed to make treatments more widely available in poor countries.
Dec 10- AbbVie Inc's all-oral hepatitis C therapy cured 96 percent of difficult-to-treat patients in a late-stage clinical trial after 12 weeks, keeping the company well placed in a highly competitive race to deliver new treatments for the serious liver disease.
Dec 6- U.S. regulators on Friday approved Gilead Sciences Inc's Sovaldi as a potentially easier cure for chronic infection with the liver-destroying hepatitis C virus. Most patients will be treated with the $1,000- a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller.
*Two or 3 more deals and Compugen could turn a profit. TEL AVIV, Nov 25- Israel's Compugen, which is trying to develop commercial drugs using computer models, says it could turn a profit if it can secure two or three more deals like its recent partnership with Bayer in immuno-oncology.
LONDON, Nov 22- European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.
The "C" class has been teaching the rest of the market a lesson this year, leading the way with oversized gains.
Nov 18- AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. AbbVie shares rose 3 percent. Shares of Enanta Pharmaceuticals Inc, which collaborates with AbbVie on one of the drugs included in the treatment, rose 4 percent.
Does the jobs report suggest the economy is kicking back into gear? Find out in the week ahead.
Nov 7- Bristol-Myers Squibb Co said on Thursday that it would no longer conduct research to discover new drugs for hepatitis C, diabetes and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer.
ZURICH, Nov 4- Swiss drugmaker Roche will pay up to 500 million Swiss francs for an experimental antibiotic, marking a rare foray by a major pharmaceutical firm into the battle against so-called "superbug" infections found in hospitals. The World Health Organisation has warned of the growing public health threat from drug-resistant superbugs.
*Experimental drug mimics GLP-1 and GIP hormones. LONDON, Oct 30- An experimental drug that mimics the effects of two naturally occurring hormones appears to work significantly better than existing single-hormone medicines against diabetes and obesity, scientists said on Wednesday.
Some stocks are hard at work making shareholders money. And they don't show any signs of stopping.
Oct 29- Vertex Pharmaceuticals Inc lowered its full-year revenue forecast and said it would cut about 15 percent of its workforce after sales of its hepatitis C drug plunged in the third quarter. The company's hepatitis C treatment, Incivek, was hugely popular when it was launched in May 2011 and revenue from the drug topped $1 billion in a few months.
Stocks were slightly higher Monday, with the S&P 500 pushing to a fresh high, but gains were limited as investors digested a batch of mixed earnings reports and ahead of the Federal Reserve's policy-setting meeting.
Take a look at some of Monday's midday movers:
WASHINGTON, Oct 25- A federal advisory panel recommended on Friday that the U.S. Food and Drug Administration approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir, paving the way for a treatment that is more effective than current therapies and takes less time.
WASHINGTON, Oct 25- A federal advisory panel recommended on Friday that U.S. health regulators approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir, paving the way for a treatment that is more effective and shorter in duration than current therapies. The FDA is not bound to follow the advice of its panels but typically does so.
Oct 23- Bristol-Myers Squibb Co reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs, but weak demand for its new Eliquis blood clot medicine dampened investor enthusiasm.